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LETTERS TO THE EDITORRegarding “Growth predictors and prognosis of small
abdominal aortic aneurysms”
The well-designed study by Schlösser et al showed that statins
appear to be associated with slower abdominal aortic aneurysm
(AAA) expansion rates.1 During a median surveillance period of
3.3 years (range: 0.5 to 11 years), a mean AAA expansion rate of
2.5  3.2 mm/year was reported.1 Despite the wide variation in
AAA growth rates between individuals (standard deviation, 3.2
mm/year, range: from 7.8 to 19 mm/year), statin use was
associated with slower AAA expansion rates (mean difference
between statin users and non-users: 1.21 mm/year; 95% confi-
dence interval, 0.19 to 2.24 mm/year; P  .02).1 As the authors
themselves also supported,1 these results are in accordance with
other recent studies showing that statins are associated with re-
duced AAA expansion rates.2,3
A possible drawback is that all these reports1-3 are observa-
tional studies; as the authors themselves conclude, “given the
inherent limitations of observational cohort studies, the apparent
slowing effect of statins on AAA growth rate needs ideally confir-
mation by a randomized placebo-controlled trial. However, as the
majority of the patients with an AAA are nowadays treated with
statins, this would hardly be possible in a placebo-controlled
design.”1 Besides this, a fact that would render difficult (if not
impossible) the design of such a study, is ethical limitations; given
the uniform positive results from observational studies,1-3 there
would probably be ethical restrictions in designing randomized
placebo-controlled trials to confirm the beneficial effects of statins
on AAA expansion rates. For this reason, the effect of statins on
AAA growth rates may never be tested in placebo-controlled
studies. However, even if statins do not attenuate AAA expansion
rates (as seen in observational studies),1-3 there is evidence suggest-
ing that routine statin treatment is associated with improved
perioperative and long-term mortality and morbidity rates should
these patients eventually undergo surgery (or endovascular AAA
repair).4,5 For this reason alone, the conservative management of
patients with small AAAs should probably include routine statin
use.
Kosmas I. Paraskevas, MD, FASA
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Reply
We would like to thank Dr Paraskevas for the kind response to
our article on growth predictors and prognosis of small abdominal
aortic aneurysms (AAA). We agree with the author’s opinion that
a placebo-controlled randomized trial in this setting cannot be
justified anymore. Moreover, given the existing evidence of bene-
ficial effects of statins in patients with vascular diseases, including
AAA, and the still existing medical undertreatment of these pa-
tients, we underscore that statin treatment should be standard in
each patient without contraindication.
A slower expansion of the aneurysm diameter is likely to
benefit the patient because the risk of rupture will be reduced and
surgery can be prevented in some patients because the diameter of
the aneurysm does not cross the threshold for surgery.1 In addition
to potential benefits of statins in survival of patients after surgical
exclusion of AAA, statins may preserve the renal function after
suprarenal aortic cross clamping.2
The mechanism of statins in reducing AAA growth and mor-
bidity and mortality after surgery is not yet understood, and
differences between types of statins have been described.3 To
further increase the prognosis of patients with small abdominal
aortic aneurysms, future randomized trials may determine if vari-
ous statin therapies are associated with different reductions in
growth rates and clinical outcomes in patients with AAA.
Felix J.V. Schlösser, MD
Marco J.D. Tangelder, MD, PhD
Frans L. Moll, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands
REFERENCES
1. Mosorin M, Niemela E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, et al.
The use of statins and fate of small abdominal aortic aneurysms. Interact
Cardiovasc Thorac Surg 2008 [Epub ahead of print].
2. Schouten O, Kok NF, Boersma E, Bax JJ, Feringa HH, Vidakovic R,
et al. Effects of statins on renal function after aortic cross clamping during
major vascular surgery. Am J Cardiol 2006;97:1383-5.
3. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic
R, et al. Effect of statin withdrawal on frequency of cardiac events after
vascular surgery. Am J Cardiol 2007;100:316-20.
doi:10.1016/j.jvs.2008.06.046
Regarding “Delayed presentation of aortic injury by
pedicle screws: Report of two cases and review of the
literature”
We read with great interest the recent article by Kakkos and
Shepard,1 which is a timely reminder of the vascular implications of
misplaced thoracic pedicle screws now widely used in spine surgery.
Thoracic pedicle screws have numerous advantages over
hooks, including stronger three column fixation, improved curve
correction both in the coronal and axial planes, and the potential to
save fusion levels. However, misplacement rates vary from a low of
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